Bremelanotide (PT-141, Vyleesi) — Research Compounds Library | RetatrutideCompare

Cyclic heptapeptide melanocortin-receptor agonist (MC4R-preferring). FDA-approved in 2019 for premenopausal hypoactive sexual desire disorder (HSDD). Self-administered subcutaneously 45 min before activity.